详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma.

184| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Rheumatology and Immunology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China [2]Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China [3]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China [4]School of Medicine, University of Electronics and Technology of China, Chengdu 610041, China [5]School of Medicine, Faculty of Medicine and Health, The University of Leeds, Leeds LS2 9JT, United Kingdom [6]Department of Breast Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China [7]Institute of Organ Transplantation, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, Chengdu 610072, China [8]Centre for Translational Medicine, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, Chengdu 610072, China [9]Department of Radiation Oncology, James Comprehensive Cancer Center and College of Medicine at The Ohio State University, Columbus, OH 43221, United States

出处：

DOI：

ISSN：

关键词： Hepatitis B virus HBV reactivation Rheumatic disease Hepatocellular carcinoma Disease-modifying antirheumatic drugs

摘要：

To date, an estimated 300 million people worldwide have been infected with chronic hepatitis B virus (HBV). Although anti-HBV therapies have improved the long-term survival profile of chronic carriers, viral reactivation still poses a significant challenge for preventing HBV-related hepatitis, hepatocellular carcinoma (HCC), and death. Immuno-modulating drugs, which are widely applied in managing rheumatic conditions, are commonly associated with HBV reactivation (HBVr) as a result of drug-induced immune suppression. However, there are few reports on the risk of HBVr and the medication management plan for HBV carriers, especially rheumatic patients. In this review, we summarize immuno-modulating drug-induced HBVr during rheumatoid therapy and its preventive strategies for HBVr-induced liver diseases, especially cirrhosis and HCC. These findings will assist with developing treatments for rheumatic patients, and prevent HBV-related cirrhosis and HCC.Copyright © 2022 Elsevier Ltd. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 1 区药学

最新[2023]版：

大类 | 2 区

医学

小类 | 1 区药学

JCR分区：

出版当年[2022]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 9.1 最新[2023版] 9 最新五年平均 9.3 出版当年[2022版] 8.8 出版当年五年平均 10.334 出版前一年[2021版] 9.1 出版后一年[2023版]

第一作者：

第一作者机构： [1]Department of Rheumatology and Immunology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China [2]Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China [3]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China

共同第一作者：

通讯作者：

通讯机构： [2]Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China [3]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China [7]Institute of Organ Transplantation, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, Chengdu 610072, China [8]Centre for Translational Medicine, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, Chengdu 610072, China [*1]Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma.

文献详情

相关文献